|
SG10201912074PA
(en)
|
2016-03-18 |
2020-02-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
IL265921B2
(en)
|
2016-10-14 |
2024-05-01 |
Prec Biosciences Inc |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
WO2018100558A2
(en)
|
2016-12-01 |
2018-06-07 |
Takeda Pharmaceutical Company Limited |
Cyclic dinucleotide
|
|
US11492367B2
(en)
*
|
2017-01-27 |
2022-11-08 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
US11021511B2
(en)
*
|
2017-01-27 |
2021-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
WO2019043634A2
(en)
*
|
2017-08-30 |
2019-03-07 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
JP7195317B2
(ja)
|
2017-11-10 |
2022-12-23 |
武田薬品工業株式会社 |
Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法
|
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
MX2020012964A
(es)
|
2018-06-01 |
2021-02-16 |
Eisai R&D Man Co Ltd |
Metodos para el tratamiento de cancer de vejiga.
|
|
TW202030199A
(zh)
*
|
2018-07-17 |
2020-08-16 |
美商健生生物科技公司 |
作為ｓｔｉｎｇ促效劑之環狀二核苷酸
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
MX2020013322A
(es)
|
2018-08-16 |
2021-02-22 |
Eisai R&D Man Co Ltd |
Sales de compuestos y cristales de los mismos.
|
|
US20200113912A1
(en)
|
2018-09-12 |
2020-04-16 |
Silverback Therapeutics, Inc. |
Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
|
|
AU2019344398B2
(en)
|
2018-09-21 |
2022-09-22 |
Shanghai De Novo Pharmatech Co., Ltd. |
Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
|
|
AU2019371206A1
(en)
|
2018-10-29 |
2021-05-27 |
Venenum Biodesign, LLC |
Novel sting agonists
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
TWI721623B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
TW202136261A
(zh)
|
2018-10-31 |
2021-10-01 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
CN111655712B
(zh)
*
|
2018-12-29 |
2021-02-05 |
上海济煜医药科技有限公司 |
作为肿瘤免疫类的化合物及其应用
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
KR102707808B1
(ko)
|
2019-03-07 |
2024-09-19 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
CN109929894B
(zh)
*
|
2019-04-17 |
2021-06-01 |
中国农业科学院兰州兽医研究所 |
一种猪源第二信使分子2′3′-cGAMP的制备及活性鉴定方法
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
JP7621974B2
(ja)
|
2019-05-09 |
2025-01-27 |
アリゴス セラピューティクス インコーポレイテッド |
Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
|
|
MX2021013657A
(es)
|
2019-05-10 |
2022-02-21 |
Takeda Pharmaceuticals Co |
Conjugados de anticuerpo y farmaco.
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
|
AU2020310853A1
(en)
|
2019-07-05 |
2022-01-27 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
CN119770638A
(zh)
|
2019-09-30 |
2025-04-08 |
吉利德科学公司 |
Hbv疫苗和治疗hbv的方法
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
US12410418B2
(en)
|
2019-12-06 |
2025-09-09 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
US11718637B2
(en)
|
2020-03-20 |
2023-08-08 |
Gilead Sciences, Inc. |
Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
|
|
WO2021206158A1
(ja)
|
2020-04-10 |
2021-10-14 |
小野薬品工業株式会社 |
がん治療方法
|
|
EP4149440A1
(en)
|
2020-05-11 |
2023-03-22 |
Erytech Pharma |
Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
|
|
JP2023532304A
(ja)
|
2020-07-01 |
2023-07-27 |
エーアールエス ファーマシューティカルズ オペレーションズ，インク． |
抗ａｓｇｒ１抗体コンジュゲートおよびその使用
|
|
PE20230779A1
(es)
|
2020-08-07 |
2023-05-09 |
Gilead Sciences Inc |
Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
|
|
EP4295917A3
(en)
|
2020-08-07 |
2024-02-28 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
AU2021363267A1
(en)
*
|
2020-10-20 |
2023-06-22 |
Tyligand Bioscience (Shanghai) Limited |
Multifunctional cyclic dinucleotide and use thereof
|
|
JP7397996B2
(ja)
|
2020-11-09 |
2023-12-13 |
武田薬品工業株式会社 |
抗体薬物コンジュゲート
|
|
EP4337223A1
(en)
|
2021-05-13 |
2024-03-20 |
Gilead Sciences, Inc. |
Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US20250170159A1
(en)
*
|
2023-06-30 |
2025-05-29 |
Immunogenesis, Inc. |
Compositions comprising sting agonists and methods of use for treating glioma
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|